Machado, P.M. et al. 2024. Design and rationale for a randomized, double-blind, placebo-controlled Phase 2/3 trial of oral arimoclomol in inclusion body myositis. RRNMF Neuromuscular Journal. 5, 2 (Sep. 2024). DOI:https://doi.org/10.17161/rrnmf.v4i5.16244.